Skip to main content
SpringerLink
Log in

18F-FDG PET/CT in multiple myeloma: critical insights and future directions

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jung S-H, Kwon SY, Min J-J, Bom H-S, Ahn S-Y, Jung S-Y, et al. 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging. 2019;46:107–15.

    Article  PubMed  Google Scholar 

  2. Ripani D, Caldarella C, Za T, Pizzuto DA, Rossi E, De Stefano V, et al. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation. Eur J Nucl Med Mol Imaging. 2019;46:116–28.

    Article  CAS  PubMed  Google Scholar 

  3. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–58.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–17.

    Article  PubMed  Google Scholar 

  5. Bailly C, Leforestier R, Jamet B, Carlier T, Bourgeois M, Guérard F, et al. PET imaging for initial staging and therapy assessment in multiple myeloma patients. Int J Mol Sci. 2017;18:445.

    Article  CAS  PubMed Central  Google Scholar 

  6. Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.

    Article  CAS  PubMed  Google Scholar 

  8. Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911–8. https://doi.org/10.1200/JCO.2017.72.2975.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stolzenburg A, Lückerath K, Samnick S, Speer M, Kneer K, Schmid J-S, et al. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging. 2018;45:1694–704.

    Article  CAS  PubMed  Google Scholar 

  10. Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, et al. Utility and prognostic value of 18F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018;93:1518–23.

    Article  CAS  PubMed  Google Scholar 

  11. Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54:1135–41.

    Article  PubMed  Google Scholar 

  13. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127:971–6.

    Article  CAS  PubMed  Google Scholar 

  14. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–46.

    Article  PubMed  Google Scholar 

  15. Nanni C, Zamagni E, Celli M, Caroli P, Ambrosini V, Tacchetti P, et al. The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. Clin Nucl Med. 2013;38:e74–9.

    Article  PubMed  Google Scholar 

  16. Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L, et al. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21:4384–90.

    Article  CAS  PubMed  Google Scholar 

  17. Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657–64.

    Article  PubMed  Google Scholar 

  18. Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414–21.

    Article  CAS  PubMed  Google Scholar 

  19. Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45:712–9.

    Article  PubMed  Google Scholar 

  20. Carlier T, Bailly C. State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET. Front Med (Lausanne). 2015;2:18.

    Google Scholar 

  21. Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, et al. Interim PET analysis in first-line therapy of multiple myeloma: prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study. Clin Cancer Res. 2018;24:5219–24.

    Article  PubMed  Google Scholar 

  22. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771–7.

    CAS  PubMed  Google Scholar 

  23. Nanni C, Cottereau AS, Lopci E, Bodet-Milin C, Coronado M, Pro B, et al. Report of the 6th International Workshop on PET in lymphoma. Leuk Lymphoma. 2017;58:2298–303.

    Article  PubMed  Google Scholar 

  24. Zamagni E, Nanni C, Dozza L, Carlier T, Tacchetti P, Versari A, et al. Standardization of 18F-FDG PET/CT according to Deauville criteria for MRD evaluation in newly diagnosed transplant eligible multiple myeloma patients: joined analysis of two prospective randomized phase III trials. Blood. 2018;132:257.

    Google Scholar 

Download references

Acknowledgments

This work was supported in part by grants from the French National Agency for Research (Investissements d’Avenir; IRON Labex grant no. ANR-11-LABX-0018-01, and ArronaxPlus Equipex grant no. ANR-11-EQPX-0004), and from the Institut National du Cancer (grant no. INCa-DGOS-Inserm_12558, SIRIC ILIAD).

Author information

Authors and Affiliations

  1. CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes, Nantes, France

    Clément Bailly, Thomas Carlier, Cyrille Touzeau, Philippe Moreau, Françoise Kraeber-Bodéré & Caroline Bodet-Milin

  2. Department of Nuclear Medicine, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France

    Clément Bailly, Thomas Carlier, Bastien Jamet, Françoise Kraeber-Bodéré & Caroline Bodet-Milin

  3. Department of Hematology, CHU de Nantes, 1 place Alexis Ricordeau, 44093, Nantes, France

    Cyrille Touzeau & Philippe Moreau

  4. Department of Nuclear Medicine, ICO-René Gauducheau, Boulevard Jacques Monod, 44805, Saint-Herblain, France

    Françoise Kraeber-Bodéré

Authors
  1. Clément Bailly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Carlier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bastien Jamet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cyrille Touzeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philippe Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Françoise Kraeber-Bodéré
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caroline Bodet-Milin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline Bodet-Milin.

Ethics declarations

Conflicts of interest

None.

Ethical approval

This article does not describe any studies with human participants performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bailly, C., Carlier, T., Jamet, B. et al. 18F-FDG PET/CT in multiple myeloma: critical insights and future directions. Eur J Nucl Med Mol Imaging 46, 1048–1050 (2019). https://doi.org/10.1007/s00259-019-04279-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04279-7

Search

Navigation